Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th
Heat Biologics, a clinical-stage biopharmaceutical firm, has announced that CEO Jeff Wolf will present at the Cantor Fitzgerald Global Healthcare Conference from September 27-30, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Heat Biologics, a clinical-stage biopharmaceutical firm, has announced that CEO Jeff Wolf will present at the Cantor Fitzgerald Global Healthcare Conference from September 27-30, 2021. The presentation is scheduled for September 29 at 9:20 AM ET. Heat Biologics focuses on developing innovative therapies to modulate the immune system, utilizing its proprietary gp96 platform, which activates immune responses against cancer and infectious diseases. The company is advancing several candidates, including HS-110 in Phase 2 trials and additional products in various stages of development.
Details
News Market Reaction – HTBX
The recorded move for HTBX in the trading session of this news was +0.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Jeff Wolf, Chief Executive Officer of Heat Biologics, will be presenting at the Cantor Fitzgerald Global Healthcare Conference being held virtually between September 27-30, 2021.
Presentation Details:
Date: Wednesday, September 29, 2021
Time: 9:20 AM ET / 6:20 AM PT
Webcast: Cantor Global Healthcare Conference
About Heat Biologics, Inc.
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. Heat’s gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in a Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
For more information, please visit: www.heatbio.com, and also follow us on Twitter.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
investorrelations@heatbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.